Health Catalyst, Inc.HCATEarnings & Financial Report
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...
HCAT Q4 FY2025 Key Financial Metrics
Revenue
$74.7M
Gross Profit
N/A
Operating Profit
$-86.1M
Net Profit
$-91.0M
Gross Margin
N/A
Operating Margin
-115.3%
Net Margin
-121.9%
YoY Growth
-6.2%
EPS
$-1.29
Health Catalyst, Inc. Q4 FY2025 Financial Summary
Health Catalyst, Inc. reported revenue of $74.7M (down 6.2% YoY) for Q4 FY2025, with a net profit of $-91.0M (down 340.3% YoY) (-121.9% margin).
Key Financial Metrics
| Total Revenue | $74.7M |
|---|---|
| Net Profit | $-91.0M |
| Gross Margin | N/A |
| Operating Margin | -115.3% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Health Catalyst, Inc. Q4 FY2025 revenue of $74.7M breaks down across 2 segments, led by Recurring Technology at $51.9M (69.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Recurring Technology | $51.9M | 69.5% |
| Professional Services | $22.8M | 30.5% |
Health Catalyst, Inc. Revenue by Segment — Quarterly Trend
Health Catalyst, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Recurring Technology and Professional Services) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Recurring Technology | $51.9M | $52.1M | $52.9M | $51.5M |
| Professional Services | $22.8M | $24.3M | $27.8M | $27.9M |
Health Catalyst, Inc. Annual Revenue by Year
Health Catalyst, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $311.1M).
Health Catalyst, Inc. Quarterly Revenue & Net Profit History
Health Catalyst, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $74.7M | -6.2% | $-91.0M | -121.9% |
| Q3 FY2025 | $76.3M | -0.0% | $-22.2M | -29.1% |
| Q2 FY2025 | $80.7M | +6.3% | $-41.0M | -50.8% |
| Q1 FY2025 | $79.4M | +6.3% | $-23.7M | -29.9% |
| Q4 FY2024 | $79.6M | +6.0% | $-20.7M | -26.0% |
| Q3 FY2024 | $76.4M | +3.5% | $-14.7M | -19.3% |
| Q2 FY2024 | $75.9M | +3.7% | $-13.5M | -17.8% |
| Q1 FY2024 | $74.7M | +1.2% | $-20.6M | -27.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.7M | $75.9M | $76.4M | $79.6M | $79.4M | $80.7M | $76.3M | $74.7M |
| YoY Growth | 1.2% | 3.7% | 3.5% | 6.0% | 6.3% | 6.3% | -0.0% | -6.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $695.1M | $691.7M | $813.0M | $858.9M | $891.5M | $616.2M | $587.1M | $502.6M |
| Liabilities | $337.9M | $334.7M | $458.0M | $493.7M | $514.7M | $268.6M | $255.2M | $256.9M |
| Equity | $357.2M | $357.0M | $355.0M | $365.2M | $376.8M | $347.5M | $331.9M | $245.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $10.3M | $1.6M | $6.2M | $-3.5M | $280000 | $-9.0M | $-464000 | $9.9M |